Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug:97:18-25.
doi: 10.1016/j.pediatrneurol.2019.02.015. Epub 2019 Feb 23.

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review

Affiliations
Review

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review

Heather E Olson et al. Pediatr Neurol. 2019 Aug.

Abstract

Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a developmental encephalopathy caused by pathogenic variants in the gene CDKL5. This unique disorder includes early infantile onset refractory epilepsy, hypotonia, developmental intellectual and motor disabilities, and cortical visual impairment. We review the clinical presentations and genetic variations in CDD based on a systematic literature review and experience in the CDKL5 Centers of Excellence. We propose minimum diagnostic criteria. Pathogenic variants include deletions, truncations, splice variants, and missense variants. Pathogenic missense variants occur exclusively within the kinase domain or affect splice sites. The CDKL5 protein is widely expressed in the brain, predominantly in neurons, with roles in cell proliferation, neuronal migration, axonal outgrowth, dendritic morphogenesis, and synapse development. The molecular biology of CDD is revealing opportunities in precision therapy, with phase 2 and 3 clinical trials underway or planned to assess disease specific and disease modifying treatments.

Keywords: CDKL5 deficiency disorder; Clinical trials; Developmental encephalopathy; Epilepsy genetics; Epileptic encephalopathy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A) A schematic of the CDKL5 protein with variants from individuals with CDD evaluated in the CDKL5 Centers of Excellence. CDKL5 gene image adapted from prior publication. B) 3D protein structure of the CDKL5 gene (Protein Data Bank ID: 4bgq) along with position of population variation (blue spheres) from gnomAD database and variants from the COEs (red spheres). C) Highlight of variants in functional domains in the CDKL5 protein. The missense variants in CDKL5 identified in affected individuals are mapped on the 3D protein structure (protein data bank id: 4bgq) as red spheres (total 23 positions). The yellow-colored region is a nucleotide binding region (aa. 19 – 72) and we observed the disease-associated variant p.Tyr24Cys in this region. The cyan-colored site is a proton acceptor active site (aa. 135) and we observed the disease-associated variant p. Asp135Gly in this site. The green-colored region is a functionally essential DFG motif (aa. 153 – 155) and we observed the disease-associated variant p. Asp153Val in this region. The pink-colored region is the morphology (information content) or consensus sequence of phospho-Tyrosine Y171 (part of Thr-Glu-Tyr motif) (aa. 164 – 178) and we observed the disease-associated variants p.Trp176Arg, p.Tyr177His, p.Arg178Gln in this region.
Figure 1.
Figure 1.
A) A schematic of the CDKL5 protein with variants from individuals with CDD evaluated in the CDKL5 Centers of Excellence. CDKL5 gene image adapted from prior publication. B) 3D protein structure of the CDKL5 gene (Protein Data Bank ID: 4bgq) along with position of population variation (blue spheres) from gnomAD database and variants from the COEs (red spheres). C) Highlight of variants in functional domains in the CDKL5 protein. The missense variants in CDKL5 identified in affected individuals are mapped on the 3D protein structure (protein data bank id: 4bgq) as red spheres (total 23 positions). The yellow-colored region is a nucleotide binding region (aa. 19 – 72) and we observed the disease-associated variant p.Tyr24Cys in this region. The cyan-colored site is a proton acceptor active site (aa. 135) and we observed the disease-associated variant p. Asp135Gly in this site. The green-colored region is a functionally essential DFG motif (aa. 153 – 155) and we observed the disease-associated variant p. Asp153Val in this region. The pink-colored region is the morphology (information content) or consensus sequence of phospho-Tyrosine Y171 (part of Thr-Glu-Tyr motif) (aa. 164 – 178) and we observed the disease-associated variants p.Trp176Arg, p.Tyr177His, p.Arg178Gln in this region.
Figure 1.
Figure 1.
A) A schematic of the CDKL5 protein with variants from individuals with CDD evaluated in the CDKL5 Centers of Excellence. CDKL5 gene image adapted from prior publication. B) 3D protein structure of the CDKL5 gene (Protein Data Bank ID: 4bgq) along with position of population variation (blue spheres) from gnomAD database and variants from the COEs (red spheres). C) Highlight of variants in functional domains in the CDKL5 protein. The missense variants in CDKL5 identified in affected individuals are mapped on the 3D protein structure (protein data bank id: 4bgq) as red spheres (total 23 positions). The yellow-colored region is a nucleotide binding region (aa. 19 – 72) and we observed the disease-associated variant p.Tyr24Cys in this region. The cyan-colored site is a proton acceptor active site (aa. 135) and we observed the disease-associated variant p. Asp135Gly in this site. The green-colored region is a functionally essential DFG motif (aa. 153 – 155) and we observed the disease-associated variant p. Asp153Val in this region. The pink-colored region is the morphology (information content) or consensus sequence of phospho-Tyrosine Y171 (part of Thr-Glu-Tyr motif) (aa. 164 – 178) and we observed the disease-associated variants p.Trp176Arg, p.Tyr177His, p.Arg178Gln in this region.

References

    1. Wolf P, Haas HL. Effects of diazepines and barbiturates on hippocampal recurrent inhibition. Archives of Pharmacology. 1977;299:211–218. - PubMed
    1. Weaving LS, Christodoulou J, Williamson SL, et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am.J Hum. Genet 2004;75(6):1079–1093. - PMC - PubMed
    1. Laroche S. What can the long-term potentiation procedure tell us about the neural mechanisms of learning and memory? In: Will BE, Schmitt P, Dalrymple-Alford JC, eds. Brain plasticity, learning and memory. Advances in behavioral biology, vol. 28 New York: Plenum Press; 1985:139–155.
    1. Bahi-Buisson N, Villeneuve N, Caietta E, et al. Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships. Am.JMed.Genet.A 2012;158A(7):1612–1619. - PubMed
    1. Majewska MD, Bell JA. Ascorbic acid protects neurons from injury induced by glutamate and NMDA. Neuropharmacology and Neurotoxicology. 1991. - PubMed

Publication types

MeSH terms

Supplementary concepts